Nestle Health Science and Aimmune Therapeutics to research new allergy therapies

Nestle Health Science and Aimmune Therapeutics have announced a new collaboration in the field of food allergy treatment.

The strategic alliance aims to accelerate the development of innovative oral immunotherapy biologics designed to desensitise people with food allergies, while also protecting them from the consequences of accidental exposure.

Aimmune’s Characterized Oral Desensitization ImmunoTherapy (CODIT) approach to treating deadly food allergies has shown significant promise, building on research indicating that the severity of most allergies can be lessened through the oral administration of gradually increasing amounts of the allergens.

The company's lead CODIT product candidate, AR101, is designed to desensitise patients with peanut allergies, with a phase III trial of the product expected to deliver results in the fourth quarter of 2017.

As part of this alliance, Nestle is investing $145 million (116.88 million pounds) to purchase a 15 percent stake in Aimmune.

Greg Behar, chief executive officer of Nestle Health Science, said: "We are investing and innovating to change the approach to food allergy management with integrated approaches from diagnostics to nutrition solutions and now biologics, where Aimmune's proprietary approach has transformational potential."

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.